Epoxidase Inhibitor-aspirin Resistance and the Relationship with Genetic Polymorphisms: a Review

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2024 Feb 29

PMID 38420770

Authors

Xiaolin Hou

Affiliations

Soon will be listed here.

Abstract

Strokes are the leading cause of death in most regions of the world. Epoxidase inhibitors include the drug aspirin (acetylsalicylic acid). Aspirin is widely used as first-line treatment for the prevention of cardiovascular and cerebrovascular diseases in at-risk patients. However, patients using conventional doses of aspirin can still develop ischaemic cardiovascular and cerebrovascular diseases, a phenomenon known as aspirin resistance. The occurrence of aspirin resistance hinders the prevention and treatment of ischaemic cardiovascular and cerebrovascular diseases. There are many factors affecting aspirin resistance, such as sex, drug dose, metabolic disease, genetic polymorphisms, drug interactions and pharmacokinetics. Genetic polymorphism refers to the simultaneous and frequent presence of two or more discontinuous variants or genotypes or alleles in a population of organisms. Platelets contain a large number of highly polymorphic transmembrane glycoprotein receptors encoded by two or more isomeric alleles. Changes in gene polymorphisms in various pathways during platelet aggregation can lead to aspirin resistance. This narrative review describes the gene polymorphisms that have been demonstrated to be significantly associated with aspirin resistance. Research on the mechanisms of aspirin resistance and increased knowledge should provide accurate drug guidance in individuals that require first-line antiplatelet therapy.

Citing Articles

Clinical Significance and Patterns of Potential Drug-Drug Interactions in Cardiovascular Patients: Focus on Low-Dose Aspirin and Angiotensin-Converting Enzyme Inhibitors.

Anfinogenova N, Stepanov V, Chernyavsky A, Karpov R, Efimova E, Novikova O J Clin Med. 2024; 13(15).

PMID: 39124556 PMC: 11313610. DOI: 10.3390/jcm13154289.

References

Pamukcu B . A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. J Thromb Thrombolysis. 2006; 23(3):213-22. DOI: 10.1007/s11239-006-9043-2. View

Alvarez-Sabin J, Quintana M, Santamarina E, Maisterra O . Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. Cerebrovasc Dis. 2014; 37(3):181-7. DOI: 10.1159/000357662. View

Szczuko M, Koziol I, Kotlega D, Brodowski J, Drozd A . The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review. Int J Mol Sci. 2021; 22(21). PMC: 8584264. DOI: 10.3390/ijms222111644. View

Wang P, Chen H, Chen A, Tsay F, Lai K, Kao S . Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin. Biomed Res Int. 2014; 2014:616018. PMC: 4163467. DOI: 10.1155/2014/616018. View

Anderson R, Theron A, Steel H, Nel J, Tintinger G . ADP-Mediated Upregulation of Expression of CD62P on Human Platelets Is Critically Dependent on Co-Activation of P2Y1 and P2Y12 Receptors. Pharmaceuticals (Basel). 2020; 13(12). PMC: 7760858. DOI: 10.3390/ph13120420. View

Norgard N . Obesity and Altered Aspirin Pharmacology. Clin Pharmacokinet. 2017; 57(6):663-672. DOI: 10.1007/s40262-017-0611-8. View

Yao Y, Tang X, Zhang J, He C, Ma Y, Xu J . Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention. Thromb Res. 2016; 141:28-34. DOI: 10.1016/j.thromres.2016.02.031. View

Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O . Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem. 1994; 221(3):889-97. DOI: 10.1111/j.1432-1033.1994.tb18804.x. View

Yi X, Cheng W, Lin J, Zhou Q, Wang C . Interaction between COX-1 and COX-2 Variants Associated with Aspirin Resistance in Chinese Stroke Patients. J Stroke Cerebrovasc Dis. 2016; 25(9):2136-44. DOI: 10.1016/j.jstrokecerebrovasdis.2016.05.039. View

10.

Weng Z, Li X, Li Y, Lin J, Peng F, Niu W . The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS One. 2013; 8(11):e78093. PMC: 3828324. DOI: 10.1371/journal.pone.0078093. View

11.

FitzGerald R, Pirmohamed M . Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther. 2011; 130(2):213-25. DOI: 10.1016/j.pharmthera.2011.01.011. View

12.

Xu Y, Yao D, Chen W, Yan H, Zhao D, Jiang L . Using the Polymorphisms Rs12041331 and Rs2768759 as Potential Predictive Markers of 90-Day Bleeding Events in the Context of Minor Strokes and Transient Ischemic Attack. Brain Sci. 2023; 13(10). PMC: 10605279. DOI: 10.3390/brainsci13101404. View

13.

Timur A, Murugesan G, Zhang L, Aung P, Barnard J, Wang Q . P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. Int J Lab Hematol. 2012; 34(5):473-83. PMC: 3419334. DOI: 10.1111/j.1751-553X.2012.01420.x. View

14.

Wang J, Liu J, Zhou Y, Wang F, Xu K, Kong D . Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis. Sci Rep. 2019; 9(1):13177. PMC: 6739359. DOI: 10.1038/s41598-019-49123-y. View

15.

Wurtz M, Nissen P, Grove E, Kristensen S, Hvas A . Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1. PLoS One. 2014; 9(10):e111816. PMC: 4216141. DOI: 10.1371/journal.pone.0111816. View

16.

Hechler B, Gachet C . Purinergic Receptors in Thrombosis and Inflammation. Arterioscler Thromb Vasc Biol. 2015; 35(11):2307-15. DOI: 10.1161/ATVBAHA.115.303395. View

17.

Gremmel T, Frelinger 3rd A, Michelson A . Platelet Physiology. Semin Thromb Hemost. 2016; 42(3):191-204. DOI: 10.1055/s-0035-1564835. View

18.

Cuisset T, Frere C, Quilici J, Morange P, Saut N, Romero-Barra M . Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Thromb Haemost. 2007; 97(2):212-7. View

19.

Idborg H, Pawelzik S . Prostanoid Metabolites as Biomarkers in Human Disease. Metabolites. 2022; 12(8). PMC: 9414732. DOI: 10.3390/metabo12080721. View

20.

Chadha D, Sumana B, Karthikeyan G, Jayaprasad V, Arun S . Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease. Catheter Cardiovasc Interv. 2014; 88(4):E126-E131. DOI: 10.1002/ccd.25420. View